HeartSciences Debuts AI-ECG Marketplace with FDA-Cleared LVEF Algorithm and $136 Rebate
HSCS•HeartSciences released MyoVista Insights version 1.3, introducing an AI-ECG Algorithm Marketplace that integrates Bunkerhill Health’s FDA-cleared ECG-EF model for detecting LVEF ≤40% from routine 12-lead ECGs. The cloud-native platform’s SaaS model targets recurring revenue with Medicare reimbursing about $136 per AI-ECG assessment under APC 5734.
1. MyoVista Insights Version 1.3 Launch
HeartSciences released MyoVista Insights version 1.3, unveiling the AI-ECG Algorithm Marketplace that allows integration of third-party cleared algorithms into its cloud-native ECG management system. This update positions the platform as a centralized SaaS solution for distributing AI-ECG models directly into clinical workflows without requiring proprietary hardware.
2. Integration of FDA-Cleared ECG-EF Algorithm
The first algorithm onboarded is Bunkerhill Health’s FDA-cleared ECG-EF model, which detects reduced left ventricular ejection fraction (LVEF ≤40%) from routine 12-lead ECG traces. This integration makes advanced AI-based cardiac assessment accessible to large health systems, community hospitals and primary care practices.
3. SaaS Revenue and Reimbursement Outlook
HeartSciences’ recurring SaaS revenue model is bolstered by Medicare reimbursement of approximately $136 per AI-ECG assessment under APC 5734. With AI-ECG projected as a multi-billion-dollar market, expansion of the algorithm marketplace is expected to drive scalable revenue growth over coming quarters.
